Suchergebnisse - "SARFATI MIZRAHI DAVID"

PubPharm (40)

1

Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated

enthalten in: bioRxiv.org | 2024

von Torres-Flores, A. | Ontiveros-Padilla, L. | Madera-Sandoval, R. | +19

2

A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Against COVID-19 (AVX/COVID-12 “Patria”) Based on an Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects with Evidence of Previous Immunity to SARS-CoV-2

enthalten in: bioRxiv.org | 2024

von López-Macías, C. | Torres, M. | Armenta-Copca, B. | +27

3

Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination

enthalten in: bioRxiv.org | 2024

von López-Macías, C. | Torres, M. | Armenta-Copca, B. | +36

4

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

enthalten in: Europäisches Patentamt | 2024

von LOZANO DUBERNARD BERNARDO | SOTO PRIANTE ERNESTO | SARFATI MIZRAHI DAVID | +7

5

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

enthalten in: Europäisches Patentamt | 2024

von LOZANO DUBERNARD BERNARDO | SOTO PRIANTE ERNESTO | SARFATI MIZRAHI DAVID | +7

6

RECOMBINANT VACCINE AGAINST COVID-19 BASED ON A PARAMYXOVIRUS VIRAL VECTOR

enthalten in: Europäisches Patentamt | 2023

von LOZANO-DUBERNARD BERNARDO | SOTO-PRIANTE ERNESTO | SARFATI-MIZRAHI DAVID | +6

7

RECOMBINANT VACCINE AGAINST COVID-19 BASED ON A PARAMYXOVIRUS VIRAL VECTOR

enthalten in: Europäisches Patentamt | 2023

von LOZANO-DUBERNARD BERNARDO | SOTO-PRIANTE ERNESTO | SARFATI-MIZRAHI DAVID | +6

8

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico

enthalten in: NPJ vaccines | 2023

von Ponce-de-León, S. | Torres, M. | Soto-Ramírez, L. | +30

9

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

enthalten in: Europäisches Patentamt | 2023

von LOZANO DUBERNARD BERNARDO | SOTO PRIANTE ERNESTO | SARFATI MIZRAHI DAVID | +7

10

RECOMBINANT VACCINE AGAINST COVID-19 BASED ON A PARAMYXOVIRUS VIRAL VECTOR

enthalten in: Europäisches Patentamt | 2023

von LOZANO-DUBERNARD BERNARDO | SOTO-PRIANTE ERNESTO | SARFATI-MIZRAHI DAVID | +6